Who Pays My Doctor?

Healthcare provider profile · identity verified

Andreas Sidiropoulos, M.D., PH.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · DETROIT, MI · NPI 1871525832

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Andreas Sidiropoulos, M.D., PH.D. received $722,449.04 in general payments during 2025 across 580 reported records.

Vanda Pharmaceuticals Inc. accounted for 39.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 9 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Caplyta, Fanapt, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Aristada by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vivitrol by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Caplyta by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abilify Maintena by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$722,449.04

580 reported records · 7 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $282,661.3239.1%2292025
ABBVIE INC. Unresolved — no canonical attribution shown $135,979.5618.8%1302025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $114,381.3815.8%762025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $114,238.1015.8%822025
Alkermes, Inc. Unresolved — no canonical attribution shown $54,142.967.5%442025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $21,021.822.9%182025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $23.900.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$516,944.00159
Travel and Lodging$146,043.84216
Consulting Fee$28,453.0012
Honoraria$18,988.004
Food and Beverage$12,020.20189

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $282,661.32 229 2025
Source payment records
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $135,979.56 130 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $114,238.10 82 2025
Source payment records
COBENFY
Normalized: cobenfy		 Drug E.R. Squibb & Sons, L.L.C. $99,008.38 69 2025
Source payment records
LYBALVI
Normalized: lybalvi		 Drug Alkermes, Inc. $54,142.96 44 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $21,021.82 18 2025
Source payment records
ARISTADA
Normalized: aristada		 Drug Alkermes, Inc. $58.17 3 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Otsuka America Pharmaceutical, Inc. $23.90 1 2025
Source payment records
HETLIOZ
Normalized: hetlioz		 Drug Vanda Pharmaceuticals Inc. $13.08 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
ARISTADA
aristada		 2025 Aristada 2024 58
Beneficiary count suppressed		 exact normalized Medicare Part D
CAPLYTA
caplyta		 2025 Caplyta 2024 31
Beneficiary count suppressed		 exact normalized Medicare Part D
FANAPT
fanapt		 2025 Fanapt 2024 14
Beneficiary count suppressed		 exact normalized Medicare Part D
VRAYLAR
vraylar		 2025 Vraylar 2024 40
Beneficiary count suppressed		 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
ABBVIE INC.
Exact reporting entity; no affiliate inference		 2025 VRAYLAR
open payments reported associated product		 CMS Open Payments — General Payments
377741 supporting records · 62704 recipient NPIs · example record 1201352550 		Vraylar · 2024
Exact normalized brand match · 1 Part D row		 40 suppressed by CMS
Alkermes, Inc.
Exact reporting entity; no affiliate inference		 2025 ARISTADA
open payments reported associated product		 CMS Open Payments — General Payments
76041 supporting records · 17486 recipient NPIs · example record 1222428566 		Aristada · 2024
Exact normalized brand match · 1 Part D row		 58 suppressed by CMS
Alkermes, Inc.
Exact reporting entity; no affiliate inference		 2025 VIVITROL
open payments reported associated product		 CMS Open Payments — General Payments
9533 supporting records · 5661 recipient NPIs · example record 1222428584 		Vivitrol · 2024
Exact normalized brand match · 1 Part D row		 19 suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
Exact reporting entity; no affiliate inference		 2025 CAPLYTA
open payments reported associated product		 CMS Open Payments — General Payments
211855 supporting records · 46143 recipient NPIs · example record 1241243071 		Caplyta · 2024
Exact normalized brand match · 1 Part D row		 31 suppressed by CMS
Otsuka America Pharmaceutical, Inc.
Exact reporting entity; no affiliate inference		 2025 ABILIFY MAINTENA
open payments reported associated product		 CMS Open Payments — General Payments
27924 supporting records · 10497 recipient NPIs · example record 1227267721 		Abilify Maintena · 2024
Exact normalized brand match · 1 Part D row		 25 suppressed by CMS
Vanda Pharmaceuticals Inc.
Exact reporting entity; no affiliate inference		 2025 FANAPT
open payments reported associated product		 CMS Open Payments — General Payments
95605 supporting records · 21383 recipient NPIs · example record 1232940535 		Fanapt · 2024
Exact normalized brand match · 1 Part D row		 14 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Trazodone HclTrazodone Hcl20431
Invega SustennaPaliperidone Palmitate19219
Buspirone HclBuspirone Hcl12017
Quetiapine FumarateQuetiapine Fumarate11913
Paliperidone ErPaliperidone11212
OlanzapineOlanzapine9813
Quetiapine Fumarate ErQuetiapine Fumarate95suppressed
ClozapineClozapine89suppressed
Olanzapine OdtOlanzapine81suppressed
Divalproex SodiumDivalproex Sodium72suppressed
OxcarbazepineOxcarbazepine72suppressed
LamotrigineLamotrigine70suppressed
Hydroxyzine PamoateHydroxyzine Pamoate6417
RisperidoneRisperidone64suppressed
Benztropine MesylateBenztropine Mesylate60suppressed
AristadaAripiprazole Lauroxil58suppressed
Duloxetine HclDuloxetine Hcl53suppressed
Hydroxyzine HclHydroxyzine Hcl53suppressed
Sertraline HclSertraline Hcl53suppressed
Fluoxetine HclFluoxetine Hcl47suppressed
Lithium CarbonateLithium Carbonate45suppressed
Atomoxetine HclAtomoxetine Hcl41suppressed
Divalproex Sodium ErDivalproex Sodium41suppressed
VraylarCariprazine Hcl40suppressed
TopiramateTopiramate39suppressed
Clozapine OdtClozapine37suppressed
AripiprazoleAripiprazole35suppressed
Lithium Carbonate ErLithium Carbonate33suppressed
Haloperidol DecanoateHaloperidol Decanoate32suppressed
CaplytaLumateperone Tosylate31suppressed
Citalopram HbrCitalopram Hydrobromide30suppressed
Fluphenazine DecanoateFluphenazine Decanoate30suppressed
AlprazolamAlprazolam27suppressed
Fluphenazine HclFluphenazine Hcl27suppressed
Venlafaxine Hcl ErVenlafaxine Hcl27suppressed
Abilify MaintenaAripiprazole25suppressed
Bupropion XlBupropion Hcl20suppressed
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20suppressed
Prazosin HclPrazosin Hcl19suppressed
VivitrolNaltrexone Microspheres19suppressed
Asenapine MaleateAsenapine Maleate18suppressed
HaloperidolHaloperidol18suppressed
Chlorpromazine HclChlorpromazine Hcl17suppressed
Lurasidone HclLurasidone Hcl17suppressed
Memantine HclMemantine Hcl15suppressed
FanaptIloperidone14suppressed
GabapentinGabapentin14suppressed
Paroxetine HclParoxetine Hcl14suppressed
Risperdal ConstaRisperidone Microspheres14suppressed
Amitriptyline HclAmitriptyline Hcl13suppressed
RivastigmineRivastigmine13suppressed
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12suppressed
MirtazapineMirtazapine12suppressed
Trihexyphenidyl HclTrihexyphenidyl Hcl12suppressed
Guanfacine Hcl ErGuanfacine Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $722,449.04 · 580 records Vanda Pharmaceuticals Inc. ARISTADA, Auvelity, CAPLYTA, COBENFY, FANAPT, HETLIOZ, LYBALVI, REXULTI, VRAYLAR 6 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error